Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)

Treatment of Primary Sjögren Syndrome With Rituximab

(2014) Valérie Devauchelle-Pensec et al.   ANNALS OF INTERNAL MEDICINE

OP0065 Tolerance and efficacy of rituximab in primary sjogren syndrome (TEARS): Results of a randomized controlled trial

(2014) V. Devauchelle-Pensec et al.   ANNALS OF THE RHEUMATIC DISEASES

Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study)

(2014) P M Meiners et al.   ANNALS OF THE RHEUMATIC DISEASES

Effects of Hydroxychloroquine on Symptomatic Improvement in Primary Sjögren Syndrome

(2014) Jacques-Eric Gottenberg et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study

(2013) Xavier Mariette et al.   ANNALS OF THE RHEUMATIC DISEASES

EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial

(2013) R V Moerman et al.   ANNALS OF THE RHEUMATIC DISEASES

Serum Levels of Beta2-Microglobulin and Free Light Chains of Immunoglobulins Are Associated with Systemic Disease Activity in Primary Sjögren’s Syndrome. Data at Enrollment in the Prospective ASSESS Cohort

(2013) Jacques-Eric Gottenberg et al.   PLoS One

Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry)

(2013) M. Ramos-Casals et al.   RHEUMATOLOGY

European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index: A Complete Picture of Primary Sjögren's Syndrome Patients

(2013) R. Seror et al.   ARTHRITIS CARE & RESEARCH

Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab

(2012) P M Meiners et al.   ANNALS OF THE RHEUMATIC DISEASES

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response

(2012) Ronald F van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry

(2012) Jacques-Eric Gottenberg et al.   ANNALS OF THE RHEUMATIC DISEASES

EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome

(2011) R. Seror et al.   ANNALS OF THE RHEUMATIC DISEASES

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

(2011) Richard Furie et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

(2011) Sandra V Navarra et al.   LANCET

Effectiveness of rituximab treatment in primary Sjögren's syndrome: A randomized, double-blind, placebo-controlled trial

(2010) J. M. Meijer et al.   ARTHRITIS AND RHEUMATISM

Accurate detection of changes in disease activity in primary Sjögren's syndrome by the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index

(2010) Raphaèle Seror et al.   ARTHRITIS CARE & RESEARCH

EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome

(2009) R. Seror et al.   ANNALS OF THE RHEUMATIC DISEASES

Novel evidence-based systemic lupus erythematosus responder index

(2009) Richard A. Furie et al.   ARTHRITIS AND RHEUMATISM

Patient acceptable symptomatic state (PASS)

(2009) Thao Pham et al.   JOINT BONE SPINE